Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Genetic modification of T cells.

Bonini C, Brenner MK, Heslop HE, Morgan RA.

Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S15-20. doi: 10.1016/j.bbmt.2010.09.019. Review.

2.

Adoptive T cell therapy of cancer.

Brenner MK, Heslop HE.

Curr Opin Immunol. 2010 Apr;22(2):251-7. doi: 10.1016/j.coi.2010.01.020. Epub 2010 Feb 17. Review.

3.

Improving T cell therapy for cancer.

Leen AM, Rooney CM, Foster AE.

Annu Rev Immunol. 2007;25:243-65. Review.

PMID:
17129181
4.

Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Ngo MC, Rooney CM, Howard JM, Heslop HE.

Hum Mol Genet. 2011 Apr 15;20(R1):R93-9. doi: 10.1093/hmg/ddr102. Epub 2011 Mar 17. Review.

5.

Tumor ablation by gene-modified T cells in the absence of autoimmunity.

Wang LX, Westwood JA, Moeller M, Duong CP, Wei WZ, Malaterre J, Trapani JA, Neeson P, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2010 Dec 1;70(23):9591-8. doi: 10.1158/0008-5472.CAN-10-2884. Epub 2010 Nov 23.

6.

Adoptive T-cell therapy for B-cell malignancies.

Hudecek M, Anderson LD Jr, Nishida T, Riddell SR.

Expert Rev Hematol. 2009 Oct;2(5):517-32. doi: 10.1586/ehm.09.47. Review.

7.

Adoptive transfer of virus-specific and tumor-specific T cell immunity.

Berger C, Turtle CJ, Jensen MC, Riddell SR.

Curr Opin Immunol. 2009 Apr;21(2):224-32. doi: 10.1016/j.coi.2009.02.010. Epub 2009 Mar 21. Review.

8.

Genetic modification of T lymphocytes for adoptive immunotherapy.

Rossig C, Brenner MK.

Mol Ther. 2004 Jul;10(1):5-18. Review.

9.

Current status of genetic modification of T cells for cancer treatment.

Dotti G, Heslop HE.

Cytotherapy. 2005;7(3):262-72. Review.

PMID:
16081353
11.

Genetically engineered T-cells for adoptive immunotherapy.

Pule M, Bollard CM, Heslop HE.

Curr Opin Mol Ther. 2002 Oct;4(5):467-75. Review.

PMID:
12435048
12.

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM.

Cancer Immunol Res. 2014 Feb;2(2):154-66. doi: 10.1158/2326-6066.CIR-13-0027. Epub 2013 Nov 12.

13.

Is adoptive T-cell therapy for solid tumors coming of age?

Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M; EBMT STWP.

Bone Marrow Transplant. 2012 Aug;47(8):1013-9. doi: 10.1038/bmt.2011.155. Epub 2011 Aug 1. Review.

PMID:
21804611
14.

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC.

Blood. 2005 Feb 15;105(4):1622-31. Epub 2004 Oct 26.

15.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19.

16.

Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, Tsai JJ, Jenq RR, Penack O, Hanash AM, Smith OM, Piersanti K, Lezcano C, Murphy GF, Liu C, Palomba ML, Sauer MG, Sadelain M, Ponomarev V, van den Brink MR.

J Clin Invest. 2013 Jun;123(6):2654-62. doi: 10.1172/JCI66301. Epub 2013 May 15.

17.

Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.

Galvan DL, O'Neil RT, Foster AE, Huye L, Bear A, Rooney CM, Wilson MH.

PLoS One. 2015 Oct 16;10(10):e0140744. doi: 10.1371/journal.pone.0140744. eCollection 2015.

18.

Transiently redirected T cells for adoptive transfer.

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM.

Cytotherapy. 2011 May;13(5):629-40. doi: 10.3109/14653249.2010.542461. Epub 2010 Dec 21.

PMID:
21174490
19.

The use of endogenous T cells for adoptive transfer.

Yee C.

Immunol Rev. 2014 Jan;257(1):250-63. doi: 10.1111/imr.12134. Review.

PMID:
24329802
20.

Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Contreras A, Sen S, Tatar AJ, Mahvi DA, Meyers JV, Srinand P, Suresh M, Cho CS.

Cancer Immunol Immunother. 2016 May;65(5):601-11. doi: 10.1007/s00262-016-1823-8. Epub 2016 Mar 24.

Supplemental Content

Support Center